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sine);
Ultrasonic assisted
microextractionAbstract Nucleosides are characterized as biomarkers in AIDS, Alzheimer, tumor, breast cancer
and various malignant diseases. In the present work a direct method for the detection of nucleosides
(adenosine, cytidine, uridine and guanosine) from urine samples has been developed. Nucleosides
represent the extent of damage in genetic material, analysis of nucleosides by ultrasonic assisted
microextraction effectively eliminates the interfering constituent of urine. This has made it a highly
selective and sensitive method to analyze the nucleosides with a lower limit of detection 0.220 lmol/
L and Limit of quantitation 0.660 lmol/L. The method has been validated with good linearity and
correlation of coefﬁcients of the calibration curves was higher than 0.997. The coefﬁcients were in
the range of 0.11–16.92% (inter-day) and 0.38–16.43% (intra-day), respectively.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Urinary proteome analysis is an emerging ﬁeld of proteomics
in research. Nucleosides are important constituents of RNA
which can be metabolized and reutilized by nucleic acid. Sub-
units of nucleic acid are nucleosides as they consist of a nucle-obase bound to pentose sugar, and modiﬁed in various ways
during metabolism. It has been reported that liquid chroma-
tography, LC/MS, GC/MS (Ravanat et al., 1999; Pouget
et al., 2000; Evans et al., 1999) and HPLC are more sensitive
and speciﬁc for the analysis of nucleosides, although these
methods require more complex steps and time for extraction
of nucleosides from the urine. In the cases of end stage renal
disease and renal failure these nucleosides do not degrade
but excreted in the urine because of lack of speciﬁc phosphor-
ylase and serve as potential markers (Gehrke et al., 1979;
Rasmuson and Bjork, 1995).Commonly used method for uri-
nary nucleosides are HPLC/MS, LCMS, LC/ESI-MS etc. with
conventional detectors. A statistical survey states that excre-
tion of nucleosides and modiﬁed nucleosides in the urine
correlates with the severe malignancy of renal failure and
cancer in patients (Speer et al., 1979; Nakano et al., 1993).
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phore in the protein by a complex formation and change in
the structure. The result may change in ﬂuorescent intensity,
emission or excitation and this measurement provides informa-
tion of the molecule excreted in the biological ﬂuid. Cytidine,
uridine, adenosine and guanosine are four nucleosides which
are secreted and elevated during breast cancer, end stage renal
diseases kidney failure etc. (Hsu et al., 2011; Jiang and Ma,
2009). It is known that free radicals in the body react with
biomolecules and involve in damaging and lead to several
diseases through inducing kidney failure, neurodegenerative
diseases and cardiac failure (Zambonin et al., 1999; HaegeleFigure 1 Spectra of four spiked nucleosides in patients’ urine at a c
buffer. Excitation wavelength for the ﬂuorescence was 490–530 nm.
Figure 2 Effect of concentration on absorptiet al., 1998). The present method investigates the four potential
nucleosides which help in determining different stages of pa-
tients suffering from end stage renal disease without the usage
of any ion pair reagent and bulky instrument.
2. Materials and methods
2.1. Chemicals
All chemicals were prepared with Mili Q system (Milipore,
Bedford, MA, USA).The ﬂuorescamine is of analytical purityoncentration of 10 lg/L in distilled water, pH = 5 sodium acetate
on and ﬂuorescence spectra of nucleosides.
Table 1 Linearity (as coefﬁcient correlation R2), slope, limit of detection, limit of quantiﬁcation in different concentration ranges for
four nucleosides in biological matrices).
Nucleosides Urine
Concentration range (lg/L)
y= a+ bxa
R2 Slope LODb lg/L LOQc lg/L
Cytidine 1.616 0.991 1.384 1.015 3.335
Uridine 1.121 0.993 2.643 1.021 3.31
Adenosine 2.53 0.997 3.177 0.452 1.624
Guanosine 1.41 0.99 3.648 0.221 0.6606
a x= concentration, lg/L; y= peak area; a= intercept; b= slope; calibration graph constructed over six concentration levels; results are
the averages of three replicate analyses.
b LOD= limit of detection (S/N = 3), lg/L.
c LOQ= limit of quantitation (S/N = 10) lg/L.
Figure 3 Representing standard deviation and average mean difference of four nucleosides at different concentration, pH = 5.
Table 2 Intraday and inter day precision of four nucleosides.
Nucleosides Intra day Intra day
Amount
added (lg/L)
Amount
found (Average)
R.S.D
(CV %)
Amount
added (lg/L)
Amount
found (Average)
R.S.D
(CV %)
Cytidine 10 22.21 1.48 10 20.099 2.23
40 24.72 40 24.38
100 28.62 100 27.96
Uridine 10 19.45 1.91 10 19.83 4.41
40 25.37 40 25.92
100 30.24 100 30.15
Adenosine 10 16.43 0.37 10 16.16 3.14
40 22.17 40 22.63
100 28.37 100 28.44
Guanosine 10 20.08 2.59 10 20.27 1.21
40 28.14 40 28.24
100 33.35 100 34.24
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nucleoside standards i.e., cytidine (purity 99%), uridine (pur-
ity 99%), adenosine (purity 99%), and guanosine (purity
99%) were provided from Sisco Research Laboratory Pvt.
Ltd.2.2. Preparation of standard nucleosides solution
Urine samples from patients were collected from the Kidney
Hospital (Ahmedabad, Gujarat).The samples were stored at
Table 3 Represents the average recovery ranged 95.73–104.7%.
Nucleosides Recovery (%)
10 lg/L 40 lg/L
Average ± SD RSD (%) Average ± SD RSD (%)
Cytidine 104.75 ± 0.77 1.48 101.50 ± 0.94 1.56
Uridine 97.72 ± 0.62 1.91 96.11 ± 0.40 0.12
Adenosine 95.73 ± 0.38 0.33 80.16 ± 0.72 2.18
Guanosine 99.45 ± 0.42 2.59 89.61 ± 0.48 0.80
330 S. Jamal, Y.K. Agrawal80 C immediately after collection. We used pooled urine
from four normal female (healthy, patient) subjects. The pa-
tients were not treated with any drugs or chemicals before
the urine was collected. The frozen urine samples were thawed
and kept at room temperature for 5 min. A 500-lL aliquot of
urine was pipetted into a 1.5 mL centrifuged tube purchased
from Supelco (Bellefonte PA), capped, and then centrifuged
for 5 min at 15,000 rpm. The supernatant was ﬁltered through
a ﬁlter (Millipore). 1 mL of supernatant was collected and
derivatized with ﬂuorescamine with sodium acetate buffer for
an analysis of urinary nucleosides. 10 lg/L stock solution of
nucleosides was prepared in distilled water and kept at
20 C. The working solutions were prepared in a Mili Q sys-
tem (Milipore, Bedford, MA, USA) by diluting stock solution
to the concentration range of 5–100 lg/L (5, 10, 20, 40, 80, and
100 lg/L).
2.3. Fluorescence derivatization
100 ll of supernatant potion of standard analyte was mixed
with 850 ll of sodium acetate buffer and 50 ll of ﬂuorescene.
Then, mixture liquid was incubated for 2–6 min simulta-
neously and the ﬁnal solution analyzed by a spectroﬂuorome-
ter (JASCO FP-6500).3. Results and discussion
Identiﬁcation and quantiﬁcation of nucleosides were deter-
mined by comparing the standard nucleoside solution with
spiked urine sample. Using our method, we can detect four
nucleosides in the urine of patients without tedious extraction
process and act as potential biomarkers for determination of
end stage renal diseases as shown in Fig. 1.
3.1. Linearity
Calibration curves were plotted between the concentration
1 · 109–1 · 103 M of four nucleosides and found to be recti-
linear over the range of 10–100 lmol/L as shown in Fig. 2.
The correlation coefﬁcient (R2) was higher than 0.987, limit
of detection (LOD) and limits of quantiﬁcation (LOQ) are gi-
ven in Table 1.
3.2. Precision
The precision of analytical method was determined by com-
paring the retention time of nucleoside standard and was
determined in triplicate for validation. The coefﬁcient of var-
iation CV% within a day was in the range of 0.37–2.59%.Table 2 represents interday and intraday repeatability in
terms of percentage RSD in retention time and peak area
as shown in Fig. 3. Inter day repeatability was measured
for 30 days as shown in Table 2. The data satisﬁed the cri-
teria of 15% (CV) for both within day and intraday
validation.
3.3. Recovery
The extraction recoveries were determined by comparing the
corrected peak areas of nucleosides extracted from spiked ur-
ine samples with those of unextracted standard containing
the same amount of nucleosides. For the determination of
nucleosides in the urine three replicate analyses of samples
spiked at the concentration of 5 and 10 lmol/mL were carried
out. The same procedure for the sample preparation and deriv-
atization as described in the previous section is shown in
Table 3.
4. Conclusion
Our method provides a direct measurement of nucleosides,
compared to other detection methods. This process has its
ability to ﬁnd early diagnostic markers because this biologi-
cal specimen is not easy to collect, analyze and requires
many complex steps to extract. The absorption of ﬂuores-
cence spectra decides the constant release of nucleosides
from the urine in kidney patients as early diagnostic markers
in ESRD. The validated method was shown to have sufﬁ-
cient selectivity and sensitivity to quantify the selected
nucleosides in the human urine. The developed method
was simple, selective, and reproducible with good recovery.
The linearity and reproducibility were also acceptable in
the linear range from 0.2–400 lmol/L.(Lee et al., 2004)
Therefore, our area of potential study states that damage
and repair of biomolecules leads to diseased condition. We
conclude that this method is reliable in assessing the urinary
proﬁles of these nucleosides for diagnosis of several diseases.Acknowledgment
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